US FDA approves Gilead’s twice-yearly injection for HIV prevention

rapplerdotcom

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection.  Full story: https://www.rappler.com/science/life-health/united-states-fda-approve-injection-hiv-prevention/

Transcript

00:00The U.S. Food and Drug Administration approves Wednesday, June 18, Gilead Sciences' lenacapavir,

00:06a twice-yearly injection, for preventing HIV infection. It will be sold under the brand

00:12name Yez2Go in the U.S. at a list price of $28,218 a year. Lenacapavir, part of a class

00:19of drugs known as capsid inhibitors, proved nearly 100% effective at preventing HIV in

00:25large trials in 2024. Kevin Robert Frost, CEO of the Foundation for AIDS Research,

00:31says Yez2Go will, quote, only be as effective as it is accessible and affordable. He calls on Gilead

00:38and the U.S. government to make sure people who want lenacapavir can get it. Gilead says it is

00:43working to secure health insurer coverage, and it will provide copay assistance for eligible insured

00:48people. It adds the drug may be available free of charge for some under its program for the uninsured.

00:55of the uninsured.

Category

Transcript

Recommended